Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Mesoblast limited    MSB   AU000000MSB8

MESOBLAST LIMITED (MSB)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Securities Exc…
12/07/2017 12/08/2017 12/11/2017 12/12/2017 12/13/2017 Date
1.33(c) 1.345(c) 1.38(c) 1.365(c) 1.395 Last
525 134 909 770 1 509 742 568 064 479 160 Volume
-0.37% +1.13% +2.60% -1.09% +2.20% Change
More quotes
Financials ( AUD)
Sales 2018 42,9 M
EBIT 2018 -78,1 M
Net income 2018 -107 M
Finance 2018 50,4 M
Yield 2018 -
Sales 2019 63,5 M
EBIT 2019 -67,4 M
Net income 2019 -47,3 M
Debt 2019 5,44 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 13,7x
EV / Sales2019 10,2x
Capitalization 640 M
More Financials
Company
Mesoblast Ltd. engages in the research, development, and market of pharmaceutical products.Its medicines target the cardiovascular conditions, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.The company was founded by Itescu Silviu on June 8, 2004 and... 
More about the company
Surperformance© ratings of Mesoblast limited
Trading Rating : Investor Rating :
More Ratings
Latest news on MESOBLAST LIMITED
12/11 MESOBLAST : Named Global Technology Leader in Cell Therapy Industry
12/07 Mesoblast Named Global Technology Leader in Cell Therapy Industry
11/17 MESOBLAST : Operational Highlights and Financial Results for the First Quarter E..
11/16 Chairman’s Address to the Mesoblast 2017 Annual General Meeting
11/14 Mesoblast Operational Highlights and Financial Results for the First Quarter ..
11/13 Mesoblast to Host First Quarter Financial Results Webcast and Conference Call
11/11 MESOBLAST : Phase 2 Trial Results Show Early and Durable Effects of Single Mesen..
11/10 Mesoblast Phase 2 Trial Results Show Early and Durable Effects of Single Mese..
11/09 Mesoblast Presents Corporate Update at 26TH Annual Credit Suisse Healthcare C..
10/02 MESOBLAST LIMITED : - End Stage Heart Failure Trial Completes Enrollment 28 Sept..
More news
Sector news : Biotechnology & Medical Research - NEC
04:46a REGENERON PHARMACEUTICALS : France's Sanofi pins hopes on new drugs after setbac..
12/12 Sanofi investors hungry for drug progress and deal news
12/08 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/15 Mesoblast 2018 Q1 - Results - Earnings Call Slides
11/15 Mesoblast's (MESO) CEO Silviu Itescu on Q1 2018 Results - Earnings Call Trans..
11/14 Mesoblast beats by $0.25, beats on revenue
11/10 Mesoblast's MPC therapy shows durable effect in mid-stage RA study; shares ah..
10/31 BONE THERAPEUTICS : Deeply Undervalued Early Stage Biotech
Chart MESOBLAST LIMITED
Duration : Period :
Mesoblast limited Technical Analysis Chart | MSB | AU000000MSB8 | 4-Traders
Technical analysis trends MESOBLAST LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 3,29  AUD
Spread / Average Target 141%
EPS Revisions
Managers
NameTitle
Silviu Itescu Chief Executive Officer, MD & Executive Director
Brian Jamieson Non-Executive Chairman
Paul Hodgkinson Chief Financial Officer
Donna L. Skerrett Chief Medical Officer
Paul Simmons Head-Research & New Product Development
Sector and Competitors
1st jan.Capitalization (M$)
MESOBLAST LIMITED-2.52%488
CELLTRION, INC.--.--%23 085
IQVIA HOLDINGS INC32.70%21 148
INCYTE CORPORATION-5.43%20 523
LONZA GROUP57.44%19 299
ALNYLAM PHARMACEUTICALS, INC.243.83%12 606